ERBB2 and breast cancer: Simultaneously, the CLEOPATRA study for metastatic HER2-positive BC reported the efficacy of dual HER2 blockade by T-mab and P-mab, suggesting that this strategy may lead to a cure for HER2-positive BC [7].